Tolerability of a four week treatment with asasantin extended released 200/25 mg capsules b.i.d, compared to reduced dose during the first two week of treatment in a double-blind, randomized placebo controlled parallel group comparison trial among Taiwanese patients with previous TIA (transient ischaemic attack) and Apos or ischemic stroke

Trial Profile

Tolerability of a four week treatment with asasantin extended released 200/25 mg capsules b.i.d, compared to reduced dose during the first two week of treatment in a double-blind, randomized placebo controlled parallel group comparison trial among Taiwanese patients with previous TIA (transient ischaemic attack) and Apos or ischemic stroke

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Aspirin/dipyridamole (Primary)
  • Indications Stroke; Transient ischaemic attacks
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 27 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top